AI brief of an SEC Form 8-K · Microchip Technology (MCHP)

Microchip prices $800 million of 0% convertible notes due 2030, with $100 million option exercised

Neutral Impact 3 of 5 financing Written later

Microchip agreed to sell $800 million of 0% convertible senior notes due 2030, and the initial purchasers exercised in full their option for an additional $100 million on February 10, 2026. The company reports net proceeds of approximately $883.3 million, with about $68.0 million used for capped call transactions and the remainder intended to repay commercial paper. Shareholders could face dilution if the notes convert at the initial conversion price of about $104.17 per share, though the capped calls are generally expected to reduce that potential dilution up to a cap price of $148.82 per share.

Key points

  • $800 million of notes sold, plus a $100 million option exercised in full on February 10, 2026; notes mature February 15, 2030
  • Net proceeds of approximately $883.3 million; about $68.0 million used for capped call transactions
  • Initial conversion price of about $104.17 per share, a 40.0% premium to the $74.41 last reported sale price on February 9, 2026
  • Company may not redeem the notes before February 20, 2029; holders may require repurchase on February 15, 2029

The filing

CompanyMicrochip Technology (MCHP)
Form8-K, current report
Filed with the SECFeb 11, 2026, 4:41 PM ET
Accession number0001193125-26-046713

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.